Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Analyst sets a new $70 price target, citing strong revenue forecasts and potential for margin expansion for the airline carrier.
Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.
Analyst cites a 'stronger for longer' demand cycle for hard disk drives, fueled by the explosive growth of cloud computing and AI.
Analysts cite strong fundraising and execution as key drivers for the alternative asset manager's upgraded rating and bullish outlook.
Irenic Capital reveals a 2% stake, urging the software firm to overhaul its board and explore strategic options after a period of underperformance.
The partnership aims to co-develop full-stack AI infrastructure, targeting enterprise and industrial use cases in Japan and beyond.
The ISM Services PMI unexpectedly fell to the breakeven point of 50, missing market forecasts and raising new questions about US economic momentum.